Why Tracer?

Fastest In-Human

Accelerating decisions by imaging drug binding

Learn how
Latest news | See all news

At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques.

By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process.

We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable.

Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.



5 differences between Phase 1 0 in drug development

Bob Wesdorp
Targeted optical fluorescence imaging: a meta‑narrative review and future perspectives.
Schouw, H. M., Huisman, L. A., Janssen, Y. F., Slart, R. H. J. A., Borra, R. J. H., Willemsen, A. T. M., Brouwers, A. H., van Dijl, J. M., Dierckx, R. A., van Dam, G. M., Szymanski, W., Boersma, H. H., Kruijff, S. European Journal Of Nuclear Medicine And Molecular Imaging. doi: 10.1007/s00259-021-05504-y